Oncogenic transcription factors are commonly activated in acute leukemias and subvert normal gene expression networks to reprogram hematopoietic progenitors into preleukemic stem cells, as exemplified by LIM-only 2 (LMO2) in T-cell acute lymphoblastic leukemia (T-ALL). Whether or not these oncoproteins interfere with other DNA-dependent processes is largely unexplored. Here, we show that LMO2 is recruited to DNA replication origins by interaction with three essential replication enzymes: DNA polymerase delta (POLD1), DNA primase (PRIM1), and minichromosome 6 (MCM6). Furthermore, tethering LMO2 to synthetic DNA sequences is sufficient to transform these sequences into origins of replication. We next addressed the importance of LMO2 in erythroid and thymocyte development, two lineages in which cell cycle and differentiation are tightly coordinated. Lowering LMO2 levels in erythroid progenitors delays G1-S progression and arrests erythropoietin-dependent cell growth while favoring terminal differentiation. Conversely, ectopic expression in thymocytes induces DNA replication and drives these cells into cell cycle, causing differentiation blockade. Our results define a novel role for LMO2 in directly promoting DNA synthesis and G1-S progression.
Oncogenic transcription factors are commonly activated in acute leukemias and subvert normal gene expression networks to reprogram hematopoietic progenitors into preleukemic stem cells, as exemplified by LIM-only 2 (LMO2) in T-cell acute lymphoblastic leukemia (T-ALL). Whether or not these oncoproteins interfere with other DNA-dependent processes is largely unexplored. Here, we show that LMO2 is recruited to DNA replication origins by interaction with three essential replication enzymes: DNA polymerase delta (POLD1), DNA primase (PRIM1), and minichromosome 6 (MCM6). Furthermore, tethering LMO2 to synthetic DNA sequences is sufficient to transform these sequences into origins of replication. We next addressed the importance of LMO2 in erythroid and thymocyte development, two lineages in which cell cycle and differentiation are tightly coordinated. Lowering LMO2 levels in erythroid progenitors delays G1-S progression and arrests erythropoietin-dependent cell growth while favoring terminal differentiation. Conversely, ectopic expression in thymocytes induces DNA replication and drives these cells into cell cycle, causing differentiation blockade. Our results define a novel role for LMO2 in directly promoting DNA synthesis and G1-S progression.
LMO2 | cell cycle | DNA replication | hematopoietic cells | T-cell acute lymphoblastic leukemia M ore than 70% of recurring chromosomal translocations in T-cell acute lymphoblastic leukemia (T-ALL) involve transcription factors that are master regulators of cell fate. These oncogenic transcription factors determine the gene signature and leukemic cell types (1) . Whether these DNA-bound factors may have additional roles beyond modulating gene expression remains unknown. LMO2, a 17-kDa protein defined by tandem zinc finger domains, is an essential nucleation factor that assembles a multipartite transcriptional regulatory complex on gene regulatory regions via direct interaction with the TAL1/SCL transcription factor, LDB1, and other DNA binding transcription factors (2-4, reviewed in refs. 5, 6) . These complexes drive gene expression programs that determine hematopoietic cell fates at critical branchpoints both during embryonic development (7) and in adult hematopoietic stem cells (8, 9) . Lmo2 function is essential in highly proliferative erythroid progenitors (10, reviewed in refs. 5, 6) . Interestingly, Lmo2 down-regulation is required for terminal erythroid differentiation (11, 12) . Because commitment to terminal differentiation is coordinated with growth arrest (13) , Lmo2 may have additional molecular functions that impede this critical step marked by growth cessation.
In mouse models of T-ALL, LMO1 or LMO2 collaborates with SCL to inhibit the activity of two basic helix-loop-helix (bHLH) transcription factors that control thymocyte differentiation, E2A/ TCF3 and HEB/TCF12, causing differentiation arrest (reviewed in ref. 14) . However, this inhibition is not sufficient, per se, for leukemogenesis, because both TAL1 and LYL1 inhibit E proteins but require interaction with LMO1/2 to activate the transcription of a self-renewal gene network in thymocytes (15, 16) and to induce T-ALL (17, 18) . Of note, downstream target genes cannot substitute for LMO1/2 to induce T-ALL, suggesting additional functions for LMO1/2.
Together, these studies underscore the dominant oncogenic properties of LMO2, as revealed by recurring retroviral integrations upstream of LMO2 in the gene therapy trial (19, 20) or by recurrent chromosomal rearrangements in T-ALL (21) . As a consequence, LMO2 is misexpressed in the T lineage, where it is normally absent. In addition, LMO proteins are frequently deregulated in breast cancers (22) and neuroblastomas (23) , pointing to their importance in cell transformation. In particular, in patients who eventually developed T-ALL associated with LMO2 activation after gene therapy, T-cell hyperproliferation was observed early during the preleukemic stage (19) . How LMO2 affects erythroid progenitor or T-cell proliferation cannot be inferred from its downstream target genes (12, (24) (25) (26) (27) (28) .
To understand LMO2 functions, we performed an unbiased screen for LMO2 interaction partners. We show that LMO2 associates with three replication proteins, minichromosome 6 (MCM6), DNA primase (PRIM1), and DNA polymerase delta (POLD1), and that LMO2 influences cell cycle progression and DNA replication in hematopoietic cells, indicating an unexpected function for LMO2.
Significance
Understanding how cell cycle and cell differentiation are coordinated during normal hematopoiesis will reveal molecular insights in leukemogenesis. LIM-only 2 (LMO2) is a transcriptional regulator that controls the erythroid lineage via activation of an erythroid-specific gene expression program. Here, we uncover an unexpected function for LMO2 in controlling DNA replication via protein-protein interactions with essential DNA replication enzymes. To our knowledge, this work provides the first evidence for a nontranscriptional function of LMO2 that drives the cell cycle at the expense of differentiation in the erythroid lineage and in thymocytes when misexpressed following genetic alterations. We propose that the nontranscriptional control of DNA replication uncovered here for LMO2 may be a more common function of oncogenic transcription factors than previously appreciated.
Results

Identification of New LMO2 Protein-Protein Interactions in Hematopoietic
Progenitors. Lmo2 is expressed in c-Kit + hematopoietic stem and progenitor cells (HSPCs) and in immature prothymocytes, but not at later stages of T-cell differentiation (29) . To identify new LMO2 binding proteins in HSPCs, we constructed a cDNA library from purified murine Kit
+
Lin
− hematopoietic progenitors for a yeast twohybrid screen and used LMO2 as bait. In addition to known LMO2-interacting proteins, such as LDB1, and to proteins associated with transcription, we unexpectedly identified interactions with three essential components of prereplication complexes (pre-RCs), namely, MCM6, POLD1, and PRIM1 (30) (Fig. 1A and Table S1 ). In comparison, a screen performed using GAL4-SCL identified only known interactions (Table S1 ). LMO2 interaction was specific to these three replication proteins, as confirmed by independent yeast two-hybrid assays with full-length cDNAs ( Fig. 1 B and C) . In addition, we identified BAZ1A/ACF1, required for DNA replication through heterochromatin (31); SetD8, for replication licensing (32); MYST2/HBO1, controlling MCM loading via ORC1 binding (33) ; and CCNA2-CDK1, regulating origin firing (34) (Fig. 1A) . The topranking pathways by gene set enrichment analysis were cell cycle, DNA synthesis, and DNA replication (Fig. 1D) , concurring with the view that LMO2 controls these processes via its protein partners. Finally, LMO2 coimmunoprecipitated with PRIM1, MCM6, and MYST2 in mammalian cells, and both LIM domains contributed to this interaction (Fig. 1E) , whereas LDB1 binding required mostly LIM1, as expected (4) . We conclude that in addition to its association with transcription regulators, LMO2 engages in protein-protein interactions with DNA replication proteins.
LMO2 Associates with Replication Complexes. We next addressed the question of whether LMO2 associates with the pre-RC in hematopoietic cells. Because pre-RC formation often requires a DNA template (35), we prepared DNA-containing chromatin extracts from CD34 + Kit + progenitors (TF-1 cells) (3, 13, 36, 37) to assess the interaction of LMO2 with endogenous replication proteins by immunoprecipitation. We found that POLD1, PRIM1, and MCM6, but not lamin B or beta-actin (negative controls), reproducibly and specifically coimmunoprecipitate with LMO2, but not with control Ig, in TF-1 chromatin extracts (Fig. 1F) . We also detected the other members of the MCM hexameric complex (MCM2-MCM7), as well as ORC2, CDC6, CDT1, and PCNA, albeit with weaker efficiency for the latter three (Fig.  1F) . In contrast, MCM6, POLD1, and PRIM1 did not coimmunoprecipitate with SCL ( Fig. 1G) , whereas LMO2 and LDB1 were found with SCL in this assay, as expected. Therefore, replication proteins do not stably associate with the SCL transcription complex but more specifically with LMO2.
LMO2 Binds to Origins of Replication. LMO2 shares important transcriptional targets with SCL (15, 16, 25, 36) . Nonetheless, LMO2 is rarely found at gene promoters (3%) by ChIP sequencing in multipotent progenitors, whereas SCL is more frequently observed within transcriptional start sites (28%) (24) , suggesting that LMO2 has SCL-independent functions. We assessed whether LMO2 associates with DNA replication origins, using ChIP of TF-1 cells with anti-LMO2, or anti-MCM5 antibodies. We first studied seven well-characterized human DNA replication origins (38) and found that both MCM5 and LMO2 occupied four of these replication origins, c-MYC, G6PD, TOP1, and MCM4 ( Fig. 2A) , all mapping to early replicating G1 (ERG1) segments (39, 40) (Fig.  S1A) . In contrast, MCM5 did not bind the GYPA promoter, a welldefined SCL-LMO2 transcriptional target (36), whereas LMO2 occupancy was confirmed, together with SCL and GATA1, two LMO2 transcription factor partners. SCL was detected at two of the seven tested origins, although binding was 10-to 20-fold lower compared with GYPA, whereas GATA1 binding was below the detection limit ( Fig. 2A) . Therefore, LMO2 is recruited to wellcharacterized DNA replication origins with MCM5, in the absence of GATA1 and frequently of SCL.
These results led us to assess LMO2 occupancy of replication initiation zones identified in two independent tiling array-based studies in HeLa cells, using Lambda-exonuclease digestion (38, 41) and anti-BrdU immunoprecipitation to purify origin-centered nascent DNA strands. We focused on a subset of 45 replication initiation zones that overlapped within a distance of 1 kb between the two studies ( Fig. 2B and Fig. S1 B and C). In TF-1 cells, MCM5 and LMO2 were each detected on 20 and 19 replication initiation zones, respectively, nearly half of which were positive for both (Fig. 2B) . We aligned these 45 replication initiation zones with ERG1 segments identified in mammalian cells (39, 42) and found that 68% of 
LMO2 39 LMO2-bound zones mapped to ERG1 segments, which is almost twice the percentage of ERG1 segments found in the absence of LMO2 (Fig. 2B) . Therefore, LMO2 is recruited to a significant proportion of initiation zones in TF-1 cells, corresponding, in most part, to ERG1 segments.
Tethering LMO2 to DNA Recruits Replication Proteins and Induces DNA Replication. To determine whether LMO2 tethering to DNA was sufficient to stimulate DNA replication, we optimized a synthetic DNA replication assay in mammalian cells described by Takeda et al. (43) . We assessed whether LMO2 fused to the DNA binding domain of GAL4 can drive DNA replication from GAL4 binding sites (5XUAS) in transfected 293 cells (Fig. 2C) . Newly replicated DNA is hemimethylated or unmethylated and can be distinguished from transfected, bacterially derived DNA by its resistance to Dpn1 digestion (43) . As expected, GAL4-ORC2 induced an approximately fivefold increase in newly synthesized DNA compared with control GAL4-VP16 (Fig. 2D) . In this assay, GAL4-LMO2 reproductively directed a dose-dependent increase of newly replicated DNA, reaching a maximum of eightfold (Fig. 2D) , whereas GAL4-SCL did not produce the same results. This activity was abrogated when GAL4-binding UAS sequences were mutated (Fig.  2E ) or absent (pBluescript vector). We therefore conclude that LMO2 anchoring to DNA was sufficient to direct DNA replication. LMO2-driven DNA replication occurred most likely in the absence of transcription because 293T cells lack hematopoietic transcription factors that recruit LMO2 to DNA, namely SCL and GATA1/ 2. To determine if DNA-bound GAL4-LMO2 could recruit DNA replication proteins to the UAS template, we performed DNA capture as previously described (44), using UAS sequences immobilized on beads. LMO2 recruited POLD1, MCM5, and, to a lesser extent, CDT1 and PCNA to DNA, and this recruitment required the integrity of the GAL4 binding site (Fig. 2F) . Together, our results indicate that LMO2 tethering to DNA was sufficient to nucleate the assembly of prereplication/preinitiation complexes specifically at the site of binding and to direct DNA replication.
LMO2 Expression Levels Control the Rate of DNA Synthesis and
Cellular Outcome in the Erythroid Lineage. Cell cycle is highly regulated in the erythroid lineage because ∼80% of primary proerythroblasts (E1 stage; Fig. 3A ) are in S phase, exactly at the onset of erythropoietin (Epo) dependence (45) , and this proportion sharply drops at the E3 and E4 stages of terminal differentiation. We observed that the E1 population segregated into cells with high and low endogenous LMO2 protein levels (Fig. 3B ), corresponding to high and low proportions of cells in S/G2/M (Fig. 3C) . Strikingly, LMO2 protein levels decrease from the E1 hi to E4 stage, directly correlating with a decrease in the proportion of cells in S phase (Fig. 3C) , whereas GATA1 and SCL protein levels increase (Fig. 3D ). This process is highly coordinated because most LMO2 partners identified here, including CCNA2, are synchronously down-regulated with Lmo2 during differentiation from proerythroblast to orthochromatic erythroblasts (Fig. S2) .
We addressed the functional importance of LMO2 by decreasing LMO2 protein levels in erythroid progenitors via RNAi (shRNA Lmo2) (Fig. S3A) . Lmo2 depletion in Ter119 − fetal liver erythroid progenitors decreased by twofold the proportion of cells in S phase as determined by DAPI staining and flow cytometry analysis, compared with control cells (Fig. 3E) . In addition, Lmo2 depletion almost abrogated the proliferation of primary erythroid progenitors at a key commitment step marked by Epo responsiveness (Fig. 3 F and G) , while enhancing the generation of mature E4 cells (CD71 (Fig. 3H) . Therefore, high LMO2 levels are required for the Epodependent proliferation of CD71 + erythroid precursors, whereas lowering LMO2 accelerates terminal erythroid differentiation.
Decreased LMO2 levels caused a twofold decrease in the rate of DNA synthesis monitored by the kinetics of 32 P orthophosphate incorporation into synchronized mouse erythroleukemia (MEL) cells (Fig. 3I) , without causing apoptosis (Fig. S3B) . Consequently, these cells failed to proliferate in culture (Fig. S3C) . Decreased DNA synthesis was unlikely due to decreased expression levels for replication genes assessed by RT-quantitative PCR (Fig. S3D) 
DNMT1:
GYPA promoter: (D) LMO2 fused to GAL4 stimulates the replication of a GAL4-responsive plasmid in mammalian cells. HEK293 cells were transfected with the indicated GALfusion genes. After Dpn1 digestion, Dpn1-resistant extrachromosomal DNA was quantified by real-time PCR (n = 2). P < 0.05. (E) LMO2-induced DNA replication depends on LMO2 tethering to DNA via GAL4 binding sites (UAS). The experiment was performed as in D. (F) LMO2 binding to artificial origins of replication is sufficient to recruit DNA replication proteins specifically. DNA capture was performed using immobilized WT or mutant UAS sequences on beads. Bound proteins were revealed by Western blotting. Data are the mean ± SD of at least two independent experiments performed in duplicate.
in which Lmo2 was knocked down or overexpressed, respectively (12, 46) . Furthermore, replication genes were not occupied by the SCL-LMO2 complex in leukemic T cells (25) . Together, these observations indicate a critical role for LMO2 in erythroid cell fate, via the control of DNA replication and the cell cycle that drives Epodependent expansion of erythroid progenitors while impeding their commitment to terminal maturation.
LMO2 Expression Regulates S-Phase Entry. We next addressed the importance of LMO2 levels on the kinetics of cell cycle progression (Fig. 3J) . Briefly, we found that viable MEL cells with low side and forward scatter properties are mostly in G0/G1 (Fig.  S3E) . These G0/G1 cells were purified and released in culture medium to analyze their DNA content by Hoechst staining (Fig.  S3E) . Decreased LMO2 (shRNA Lmo2) reproducibly caused a 2-h delay in G1/S transition, occurring at 3 h after release compared with 1 h for control cells (Vector), as well as delayed S-phase progression (Fig. 3J and Fig. S3E ), indicating that LMO2 levels control S-phase entry in erythroblasts.
To mimic retroviral integration upstream of the LMO2 locus in the X-SCID gene therapy trial (19, 20, 46) and define the consequences of ectopic LMO2 expression in vivo, we delivered LMO2 in hematopoietic stem cells by retroviral infection, (Fig. 4 A-F) . Upon transplantation, LMO2-transduced bone marrow cells induced T-ALL in 60% of recipient mice, with a median of 270 days (46) (Fig.  4B and Fig. S4 ). During the preleukemic stage (30 days), LMO2 overexpression mostly affected thymocytes and led to an accumulation of CD44
− double-negative thymocyte (DN) cells and a decrease in CD4 +
CD8
+ double-positive thymocyte (DP) cells in the thymus, reproducing the differentiation blockade at the DN stage reported in LMO2 transgenic mice (Fig. 4C) , despite the fact that the retroviral vector allowed for transgene expression in all cells. Elevating LMO2 in thymocytes modified the cell cycle status of thymocyte progenitors (Fig. 4D) without affecting bone marrow stem cells (Fig. S4B) , consistent with the role of LMO2 as a T-cell specific oncogene (46) . Interestingly, elevating LMO2 enhanced the cell cycle status of both DN1 and DP cells, suggesting that differentiation blockade (lower number of DP cells) could be due to increased cell cycle. Furthermore, when DN1 thymocytes were synchronized in G0/G1 and released in culture, LMO2-expressing cells entered more rapidly into S phase compared with control cells (vector) (Fig. 4E) , indicating that LMO2 facilitates the G1-S transition and S phase progression.
The above results indicate that LMO2 overexpression in hematopoietic cells reproduced the T-cell proliferation phenotype reported for preleukemic patients in the X-SCID gene therapy trial. Actively dividing cells are more sensitive to 5-fluorouracil (5-FU), an antimetabolite that inhibits thymidylate synthase and therefore depletes the pool of dTTP. Consistent with increased DNA replication, LMO2-expressing thymocytes cocultured with MS5 stromal cells expressing DL4 were 100-fold more sensitive than WT thymocytes to 5-FU (EC 50 of 5 nM vs. 500 nM) (Fig. 4F) .
Discussion
LMO2 has a well-established function in transcriptional regulation via direct interaction with transcription factors, mostly of the bHLH family, SCL/TAL1, TAL2, and LYL1 or GATA proteins (2) (3) (4) . In this study, we revealed unexpected new functions of LMO2 in hematopoiesis and leukemogenesis through a yeast two-hybrid screen of LMO2 interaction partners in hematopoietic progenitors. Our observations indicate that LMO2 controls cell fate by directly promoting DNA replication, a hitherto unrecognized mechanism that might also account for its oncogenic properties.
Our study unravels unexpected interactions between LMO2 and three essential replication proteins, MCM6, PRIM1, and POLD1 (30), as well as chromatin-modifying enzymes that have wellcharacterized roles in DNA replication, BAZ1A, SETD8, MYST2, and UHRF1 (31) (32) (33) 47) . More importantly, tethering LMO2 to DNA via the GAL4-DNA binding domain was sufficient to recruit MCM5 and POLD1 to DNA and to transform UAS into origins of replication, indicating that LMO2 directly controls DNA replication. Unlike other transcription complexes that have a dual role in DNA replication (48) , LMO2 interaction with the RC is distinct from the well-known recruitment of LMO2 to the SCL transcription complex. Our data are in line with the observations that there is only a partial overlap between SCL and LMO2 chromatin occupancy in hematopoietic progenitors (24) .
LMO2 binding to replication initiation zones reported here overlaps with early G1 replication segments described in lymphoid cells (39, 42) , a possibility that may be favored by its interaction with MLL2 (Fig. 1A) . Indeed, the H3K4me3 histone mark found in early replicating domains (40) Abundance ratio of E1-4 subsets in Lmo2 shRNA/control during a given cell cycle, which requires recruitment of DNA polymerases to initiate DNA synthesis (30) . Accordingly, we show that LMO2 levels influence the rate of DNA replication in MEL cells.
Although we focused on the basic components of the pre-RC in the present study, several other proteins identified in the screen could have a regulatory function. For example, cyclin A2-CDK2 favors the onset of DNA replication at the G1-S transition and prevents rereplication during S phase (49) . These possibilities would be consistent with the effects of LMO2 levels on the kinetics of G1-S transition that we observed in two cell types, delayed when Lmo2 is knocked down in murine erythroleukemic cells and, conversely, accelerated in LMO2-overexpressing DN1 thymocytes. In addition, LMO2 associates with two cell cycle checkpoint proteins, CDK9 and BUB1B (Table S1 ). CDK9 associates with cyclin K in replication stress response and prevents DNA damage in replicating cells (50) . BUB1B is an essential component of the mitotic checkpoint. The importance of these cell cycle proteins for LMO2-induced cell proliferation remains to be addressed.
Cell cycle is a highly regulated process in the erythroid lineage. CD71
+
Ter119
− proerythroblasts represent a critical transitional stage marked by Epo dependency (51) and elevated DNA replication (45) , both shown here to require high LMO2 protein expression. Conversely, terminal erythroid differentiation to the CD71
−
Ter119
+ stage is necessarily coordinated with growth arrest (13, 51), which we now show to be favored by Lmo2 downregulation, in agreement with previous work indicating that LMO2 overexpression prevents terminal erythroid differentiation (11) . We conclude that LMO2 down-regulation is required for the switch to terminal erythroid differentiation due to the implication of LMO2 in DNA replication/cell cycle (Fig. 4G) .
It is well established that transcription factor gene networks drive hematopoietic cell development and lineage outcome, via synergistic or antagonistic interactions (reviewed in refs. 52 and 53). It is unclear how LMO2 inhibits cell differentiation in both the erythroid (11) and T-lymphoid lineages (reviewed in ref. 53) . We now propose that LMO2-dependent DNA replication in both lineages governs the switch between a proliferative state in progenitors and commitment to terminal differentiation (Fig.  4G ). Failure to regulate this proliferative switch caused by ectopic LMO2 expression (19) may lead to T-ALL.
Oncogene-induced DNA replication stress (54) could lead to replication errors and ultimately cause genetic lesions, such as activating NOTCH1 mutations (55, 56) , that convert preleukemic stem cells (15, 16) into leukemia initiating cells (15) . Two other LIM-only proteins, LMO1 and LMO4, are also important determinants of cell cycle progression in neuroblastoma (23) and in breast cancer associated with genomic instability (22) , respectively, suggesting that the mechanism(s) described here may be extended to these proteins. Emerging evidence indicates that oncogenes, such as c-MYC or HOXD13, can be part of nontranscriptional complexes involved in DNA replication (54, 57) . Taken together, we propose that oncogenic transcription factors in acute leukemias and possibly other tumor types transform cells by at least two DNA-dependent mechanisms, the control of gene expression programs, as initially proposed (1), but also by deregulating DNA replication (42), with both processes being important determinants of cell fate.
Materials and Methods
Yeast Two-Hybrid. were isolated and sequenced. To confirm the interactions and check for specificity, full-length cDNAs for Polδ1, Prim1, Mcm2-5-6-10, Cdt1, Pcna, and Caf1 were subcloned into pGADT7 and transformed in AH109 cells.
Retroviral Gene Transfer and RNAi. LMO2 retroviral gene transfer and mouse bone marrow transplantation were performed as described (8) . For RNAi experiments, vesicular stomatitis virus (VSV-G)-producing cells were transfected with plasmids encoding shRNAs against LMO2, with a nontarget shRNA or with the empty pLKO.1 vector (Sigma). MEL cells or Lin − fetal liver cells were incubated with VSV-G supernatant for 48 h and then selected with puromycin as described (8) . All mice were kept under pathogen-free conditions according to institutional animal care and use guidelines. The protocols for gene transfer and transplantation in mice were approved by the Committee of Ethics and Animal Deontology of the University of Montreal.
Flow Cytometry, Cell Cycle Analysis, and Cell Sorting. Flow cytometry, cell cycle analysis, and cell sorting are described in Supporting Information. After proteinase K digestion and phenol/chloroform extraction, DNA was resolved on an alkaline (NaOH) agarose gel. The gel was dried on a Biodyne membrane (Pall Corporation). used are shown in Tables S2 and S3 , and Abs used for ChIP, IB, and immunofluorescence are listed in Table S4 .
Transient Replication Assay in Mammalian Cells. The transient replication assay is adapted from Takeda et al. (43) and described in Supporting Information.
